» Articles » PMID: 36386641

Polysaccharides Alleviates Lipopolysaccharides-induced Inflammatory Lung Injury by Altering Intestinal Microbiota in Mice

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2022 Nov 17
PMID 36386641
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory lung injury is a common respiratory disease with limited therapeutic effects. Increasing opinions approved that prevention is more important than drug treatment for inflammatory lung injury. polysaccharides (APS) has multiple bioactivities including anti-inflammation and immunoregulation. However, its preventive effects on inflammatory lung injury remain unclear. In this study, mice were pretreated with APS intragastric gavage and then were intratracheally instilled with lipopolysaccharides (LPS) to determine the role of APS in preventing lung injury. The results showed that APS pre-treatment improved the pathological changes of lung tissues, reduced the neutrophils infiltration, and inhibited the LPS-induced inflammation. Increasing evidence confirmed the close relationship between intestinal microbiota and lung inflammatory response. 16S rRNA analysis showed that APS treatment changed the microbiota composition in colon, increased the abundance of short-chain fatty acids (SCFAs)-producing genus such as , , and . Also, APS treatment significantly increased the serum concentrations of SCFAs including butyrate and propionate, and their anti-inflammation effects were demonstrated on mice primary alveolar macrophages. Our data confirmed the preventive effects of APS on LPS-induced lung injury, which were partly contributed by the alteration of intestinal microbiota composition and the resulting increase of serum SCFAs.

Citing Articles

Unraveling the web of defense: the crucial role of polysaccharides in immunity.

Shen Y, Zhao H, Wang X, Wu S, Wang Y, Wang C Front Immunol. 2024; 15:1406213.

PMID: 39524445 PMC: 11543477. DOI: 10.3389/fimmu.2024.1406213.


The causal relationship between the gut microbiota and acute pancreatitis: A 2-sample Mendelian randomization study.

He L, Luo H, Li Y, Zhang Y, Peng L, Xu Y Medicine (Baltimore). 2024; 103(22):e38331.

PMID: 39259083 PMC: 11142829. DOI: 10.1097/MD.0000000000038331.


Astragali radix (Huangqi): a time-honored nourishing herbal medicine.

Zhang Y, Chen Z, Chen L, Dong Q, Yang D, Zhang Q Chin Med. 2024; 19(1):119.

PMID: 39215362 PMC: 11363671. DOI: 10.1186/s13020-024-00977-z.


: A Review of Its Antitumor Effects on Non-Small Cell Lung Cancer.

Li Z, Liu J, Cui H, Qi W, Tong Y, Wang T Cancer Manag Res. 2024; 16:909-919.

PMID: 39081698 PMC: 11287463. DOI: 10.2147/CMAR.S466633.


Astragalus polysaccharide: implication for intestinal barrier, anti-inflammation, and animal production.

Liang H, Tao S, Wang Y, Zhao J, Yan C, Wu Y Front Nutr. 2024; 11:1364739.

PMID: 38757131 PMC: 11096541. DOI: 10.3389/fnut.2024.1364739.


References
1.
He X, Shu J, Xu L, Lu C, Lu A . Inhibitory effect of Astragalus polysaccharides on lipopolysaccharide-induced TNF-a and IL-1β production in THP-1 cells. Molecules. 2012; 17(3):3155-64. PMC: 6268450. DOI: 10.3390/molecules17033155. View

2.
Walters W, Xu Z, Knight R . Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett. 2014; 588(22):4223-33. PMC: 5050012. DOI: 10.1016/j.febslet.2014.09.039. View

3.
Samuelson D, Welsh D, Shellito J . Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol. 2015; 6:1085. PMC: 4595839. DOI: 10.3389/fmicb.2015.01085. View

4.
Kourkoutas Y, Karatzas K, Valdramidis V, Chorianopoulos N . Bioactive natural products: facts, applications, and challenges. Biomed Res Int. 2015; 2015:684109. PMC: 4413524. DOI: 10.1155/2015/684109. View

5.
Ferkol T, Schraufnagel D . The global burden of respiratory disease. Ann Am Thorac Soc. 2014; 11(3):404-6. DOI: 10.1513/AnnalsATS.201311-405PS. View